Eli Lilly and Company - Product Releaseshttp://newsroom.lilly.com/newslist.cfm?sh_auth=767441604.0.0.9c90276473a65356550854f18e998096en-usShareholder.com RSS FeedNew Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCIhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=425121Wed, 18 Nov 2009 18:11:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=425121New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCIEfient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Diseasehttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=424274Sun, 15 Nov 2009 21:15:44 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=424274Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery DiseaseEffient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Diseasehttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=424271Sun, 15 Nov 2009 20:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=424271Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery DiseaseAmylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Updatehttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=421030Mon, 02 Nov 2009 20:30:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=421030Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection UpdateBYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabeteshttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=420602Sat, 31 Oct 2009 00:16:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=420602BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 DiabetesAmylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=411280Thu, 24 Sep 2009 12:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=411280Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancerhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=410305Mon, 21 Sep 2009 11:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=410305Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung CancerNew Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta<font size="-1"><sup>&reg;</sup></font> http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=408681Fri, 11 Sep 2009 15:26:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=408681New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta<font size="-1"><sup>&reg;</sup></font> Know Fibro Initiative Commemorates National Pain Awareness Monthhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=407413Tue, 08 Sep 2009 12:30:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=407413Know Fibro Initiative Commemorates National Pain Awareness MonthEffient(TM) is Now Available in Pharmacieshttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=401270Wed, 05 Aug 2009 13:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=401270Effient(TM) is Now Available in Pharmacies